US FDA accepts BMS's filing of belatacept
This article was originally published in Scrip
Executive Summary
The US FDA has accepted Bristol-Myers Squibb's BLA for its injectable immunosuppressant belatacept for the prevention of organ rejection following kidney transplantation.